Literature DB >> 10435624

CBP and histone deacetylase inhibition enhance the transactivation potential of the HOXB7 homeodomain-containing protein.

A Chariot1, C van Lint, M Chapelier, J Gielen, M P Merville, V Bours.   

Abstract

Homeodomain-containing proteins are transcription factors regulating the coordinated expression of multiple target genes involved in development, differentiation and cellular transformation. In this study, we demonstrated that HOXB7, one member of this family, behaved as a transactivator in breast cancer cells. Deletion of either the HOXB7 N-terminal domain or the C-terminal acidic tail abolished this transcriptional effect, suggesting a combination of distinct functional transactivating domains. HOXB7 physically interacted both in vitro and in vivo with the coactivator CREB-binding protein (CBP). This interaction led to an enhanced transactivating potential and required the N-terminal of HOXB7 as well as two domains located at the C-terminal part of CBP. Moreover, trichostatin A, a deacetylase inhibitor, strongly enhanced the transcriptional properties of HOXB7. Our data therefore indicate that HOX proteins can directly interact with CBP and that acetylation/deacetylation may regulate their transcriptional properties.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10435624     DOI: 10.1038/sj.onc.1202776

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  17 in total

1.  The HOX homeodomain proteins block CBP histone acetyltransferase activity.

Authors:  W F Shen; K Krishnan; H J Lawrence; C Largman
Journal:  Mol Cell Biol       Date:  2001-11       Impact factor: 4.272

2.  Identification and characterization of Hoxa9 binding sites in hematopoietic cells.

Authors:  Yongsheng Huang; Kajal Sitwala; Joel Bronstein; Daniel Sanders; Monisha Dandekar; Cailin Collins; Gordon Robertson; James MacDonald; Timothee Cezard; Misha Bilenky; Nina Thiessen; Yongjun Zhao; Thomas Zeng; Martin Hirst; Alfred Hero; Steven Jones; Jay L Hess
Journal:  Blood       Date:  2011-11-09       Impact factor: 22.113

Review 3.  Role of homeobox genes in normal mammary gland development and breast tumorigenesis.

Authors:  Hexin Chen; Saraswati Sukumar
Journal:  J Mammary Gland Biol Neoplasia       Date:  2003-04       Impact factor: 2.673

4.  Pbx1 represses osteoblastogenesis by blocking Hoxa10-mediated recruitment of chromatin remodeling factors.

Authors:  Jonathan A R Gordon; Mohammad Q Hassan; Sharanjot Saini; Martin Montecino; Andre J van Wijnen; Gary S Stein; Janet L Stein; Jane B Lian
Journal:  Mol Cell Biol       Date:  2010-05-03       Impact factor: 4.272

5.  Regulation of interleukin-6 gene expression by pro-inflammatory cytokines in a colon cancer cell line.

Authors:  S Legrand-Poels; S Schoonbroodt; J Piette
Journal:  Biochem J       Date:  2000-08-01       Impact factor: 3.857

6.  Pbx1-dependent control of VMC differentiation kinetics underlies gross renal vascular patterning.

Authors:  Romulo Hurtado; Rediet Zewdu; James Mtui; Cindy Liang; Robert Aho; Chad Kurylo; Licia Selleri; Doris Herzlinger
Journal:  Development       Date:  2015-07-02       Impact factor: 6.868

7.  Cell signaling switches HOX-PBX complexes from repressors to activators of transcription mediated by histone deacetylases and histone acetyltransferases.

Authors:  M Saleh; I Rambaldi; X J Yang; M S Featherstone
Journal:  Mol Cell Biol       Date:  2000-11       Impact factor: 4.272

Review 8.  Hox specificity unique roles for cofactors and collaborators.

Authors:  Richard S Mann; Katherine M Lelli; Rohit Joshi
Journal:  Curr Top Dev Biol       Date:  2009       Impact factor: 4.897

9.  Meis cofactors control HDAC and CBP accessibility at Hox-regulated promoters during zebrafish embryogenesis.

Authors:  Seong-Kyu Choe; Peiyuan Lu; Mako Nakamura; Jinhyup Lee; Charles G Sagerström
Journal:  Dev Cell       Date:  2009-10       Impact factor: 12.270

Review 10.  Hox regulation of transcription: more complex(es).

Authors:  Franck Ladam; Charles G Sagerström
Journal:  Dev Dyn       Date:  2013-07-22       Impact factor: 3.780

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.